7 news items
Unveiling 18 Analyst Insights On Legend Biotech
LEGN
4 Jun 24
to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent
Legend Biotech Shares Data on the Earliest Use to Date of CARVYKTI® in the Treatment of Multiple Myeloma and Important Subgroup Analyses at ASCO and EHA
LEGN
3 Jun 24
® in multiple myeloma with suboptimal response after front-line ASCT featured in an oral presentation at the 2024 ASCO Annual Meeting show
Legend Biotech to Highlight Leadership in CAR-T Cell Therapy for Patients with Multiple Myeloma at ASCO and EHA
LEGN
23 May 24
had suboptimal response to frontline ASCT in an oral presentation at ASCO & EHA
Legend Biotech Stock: A Deep Dive Into Analyst Perspectives (14 Ratings)
LEGN
14 May 24
they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Legend Biotech. This information
CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma
LEGN
22 Apr 24
and sustained complete response rates following treatment.
ABOUT
gavluur7gvs37m0e0wa6oam61z4s45mqakt62md58cuy
BMY
GILD
JNJ
19 Apr 24
action” in response to clinical testing and safety monitoring reports tied to commercial use.
In January, the FDA asked
8g7hr7psfc0nq2y962biqebmndxav8jcka7wbdoc72e7fdb802y0s32ktn
LEGN
5 Apr 24
response rates following treatment.
ABOUT CARTITUDE-4
- Prev
- 1
- Next